Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans

Biolinq has announced the successful closure of a $100 million venture capital investment round aimed at finalizing the development of its wearable glucose biosensor. According to the company, the funding will support the launch of commercial operations while it prepares for regulatory submissions in the United States.
The compact biosensor, designed to be worn on the forearm, has the capability to monitor not only glucose levels but also sleep patterns and physical activity. This additional data can offer more comprehensive insight into an individual’s metabolic profile. The device utilizes a series of electrochemical sensors that can detect various biomarkers beneath the skin, including lactate and ketones, without the need to pierce the skin or access subcutaneous tissue through traditional methods.

A distinctive feature of the system is its real-time visual indicator, which changes color to reflect blood glucose status. This immediate feedback mechanism is intended to simplify how users interpret their metabolic data.
The company’s chairman, Dan Bradbury, described the platform as a significant advancement in biosensing technology. He noted that the product could benefit individuals living with Type 2 diabetes who do not rely on insulin therapy, although his comments reflect the company’s own vision rather than an independently validated clinical impact.
This latest Series C funding round was spearheaded by Alpha Wave Ventures and included contributions from a number of previous investors, such as RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.

The current investment follows an earlier round in April 2024, during which Biolinq secured $58 million to support a pivotal clinical trial. That effort was also led by Alpha Wave Ventures. Additionally, the company completed a $100 million Series B round in late 2021.
Rick Gerson, chairman of Alpha Wave Global, previously highlighted the multidisciplinary expertise assembled by Biolinq, citing the firm’s collaborations with professionals in biosensor engineering, consumer technology, material sciences, software, and semiconductor design.